Free Trial
NASDAQ:VTRS

Viatris (VTRS) Stock Price, News & Analysis

Viatris logo
$9.01 -0.11 (-1.21%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$9.01 0.00 (-0.06%)
As of 06/27/2025 06:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Viatris Stock (NASDAQ:VTRS)

Key Stats

Today's Range
$8.92
$9.17
50-Day Range
$7.57
$9.12
52-Week Range
$6.85
$13.55
Volume
17.75 million shs
Average Volume
10.98 million shs
Market Capitalization
$10.57 billion
P/E Ratio
N/A
Dividend Yield
5.33%
Price Target
$10.40
Consensus Rating
Reduce

Company Overview

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Viatris Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

VTRS MarketRank™: 

Viatris scored higher than 60% of companies evaluated by MarketBeat, and ranked 438th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Viatris has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on 1 buy rating, 2 hold ratings, and 2 sell ratings.

  • Amount of Analyst Coverage

    Viatris has only been the subject of 1 research reports in the past 90 days.

  • Read more about Viatris' stock forecast and price target.
  • Earnings Growth

    Earnings for Viatris are expected to decrease by -4.10% in the coming year, from $2.68 to $2.57 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Viatris is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Viatris is -2.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Viatris has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Viatris' valuation and earnings.
  • Percentage of Shares Shorted

    3.74% of the float of Viatris has been sold short.
  • Short Interest Ratio / Days to Cover

    Viatris has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Viatris has recently decreased by 12.97%, indicating that investor sentiment is improving significantly.
  • Dividend Leadership

    Viatris is a leading dividend payer. It pays a dividend yield of 5.26%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Viatris does not have a long track record of dividend growth.

  • Dividend Sustainability

    Based on earnings estimates, Viatris will have a dividend payout ratio of 18.68% next year. This indicates that Viatris will be able to sustain or increase its dividend.

  • Read more about Viatris' dividend.
  • Percentage of Shares Shorted

    3.74% of the float of Viatris has been sold short.
  • Short Interest Ratio / Days to Cover

    Viatris has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Viatris has recently decreased by 12.97%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Viatris has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Viatris this week, compared to 10 articles on an average week.
  • Search Interest

    18 people have searched for VTRS on MarketBeat in the last 30 days. This is an increase of 64% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added Viatris to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Viatris insiders have bought more of their company's stock than they have sold. Specifically, they have bought $536,400.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 0.13% of the stock of Viatris is held by insiders.

  • Percentage Held by Institutions

    79.88% of the stock of Viatris is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Viatris' insider trading history.
Receive VTRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viatris and its competitors with MarketBeat's FREE daily newsletter.

VTRS Stock News Headlines

The $7 company helping Nvidia build the world’s first trillion-dollar robot …
Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profitable trends in tech … well ahead of Wall Street. Like when he called Nvidia at a mere 80 cents a share. Or Bitcoin when it was trading for just $300. Throughout his illustrious career … Michael has given his followers almost 150 different chances to register triple-digit gains.
Viatris: The Problem With The Business Model
See More Headlines

VTRS Stock Analysis - Frequently Asked Questions

Viatris' stock was trading at $12.45 at the start of the year. Since then, VTRS shares have decreased by 27.6% and is now trading at $9.01.
View the best growth stocks for 2025 here
.

Viatris Inc. (NASDAQ:VTRS) announced its quarterly earnings results on Thursday, May, 8th. The company reported $0.50 EPS for the quarter, topping analysts' consensus estimates of $0.49 by $0.01. The firm's revenue for the quarter was down 10.9% compared to the same quarter last year.
Read the conference call transcript
.

Viatris' board initiated a stock buyback plan on Wednesday, February 28th 2024, which permits the company to repurchase $1,000,000,000 in shares, according to EventVestor. This means that the company could repurchase up to 6.7% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's board of directors believes its shares are undervalued.

Viatris' top institutional shareholders include Vanguard Group Inc. (12.20%), Price T Rowe Associates Inc. MD (6.28%), Davis Selected Advisers (5.48%) and Invesco Ltd. (2.26%). Insiders that own company stock include Rajiv Malik, Scott Andrew Smith, Anthony Mauro, Paul Campbell, Harry Korman, Brian Roman, Xiangyang (Sean) Ni, Dillon Joellen Lyons, Andrew Cuneo and Der Meer Mohr Pauline Van.
View institutional ownership trends
.

Shares of VTRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Viatris investors own include Pfizer (PFE), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC), Tesla (TSLA) and Walt Disney (DIS).

Company Calendar

Last Earnings
5/08/2025
Record date for 6/16 Dividend
5/23/2025
Ex-Dividend for 6/16 Dividend
5/23/2025
Dividend Payable
6/16/2025
Today
6/28/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical Services
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VTRS
Employees
32,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.40
High Stock Price Target
$13.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+15.4%
Consensus Rating
Reduce
Rating Score (0-4)
1.80
Research Coverage
5 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
3.36
P/E Growth
N/A
Net Income
-$634.20 million
Pretax Margin
-27.39%

Debt

Sales & Book Value

Annual Sales
$14.74 billion
Cash Flow
$5.03 per share
Price / Cash Flow
1.79
Book Value
$15.61 per share
Price / Book
0.58

Miscellaneous

Outstanding Shares
1,173,680,000
Free Float
1,172,156,000
Market Cap
$10.57 billion
Optionable
Optionable
Beta
0.90
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:VTRS) was last updated on 6/28/2025 by MarketBeat.com Staff
From Our Partners